Table 2. Demographics and disease... | American Society of Hematology

Table 2.

Demographics and disease history for patients experiencing severe BEs in PERSEPT 1 and PERSEPT 2

Trial	Patient	Age, y	Race	Weight, kg	Hemophilia type	Inhibitor titer, BU∗
PERSEPT 1	Patient 1	34	White	107	Severe HA	0.4†,‡
	Patient 2	50	White	47	Severe HA	2.4†
	Patient 3	31	White	71	Severe HA	0.8†
PERSEPT 2	Patient 4	9	White	52	Severe HA	8.0†
	Patient 5	8	Black or African-American	28	Severe HA	28.3
	Patient 6	1	Black or African-American	11	Severe HA	10.2
	Patient 7	6	Black or African-American	25	Severe HB	0.0†

Trial	Patient	Age, y	Race	Weight, kg	Hemophilia type	Inhibitor titer, BU∗
PERSEPT 1	Patient 1	34	White	107	Severe HA	0.4†,‡
	Patient 2	50	White	47	Severe HA	2.4†
	Patient 3	31	White	71	Severe HA	0.8†
PERSEPT 2	Patient 4	9	White	52	Severe HA	8.0†
	Patient 5	8	Black or African-American	28	Severe HA	28.3
	Patient 6	1	Black or African-American	11	Severe HA	10.2
	Patient 7	6	Black or African-American	25	Severe HB	0.0†

BU, Bethesda units.

Inhibitor titer assessment performed at screening; anamnestic and refractory response as indicated in disease history.

High anamnestic response expected.

Refractory to increased factor replacement dosing expected.